{"summary":"I am a curious, resourceful and productive PhD-level organic chemist with 2 years' industry experience in preclinical development of antibody-drug conjugates (ADCs). Building and characterizing new molecules is my passion, which cannot be achieved without collaboration from fellow scientists. I aim to leverage my diverse scientific background in chemistry, molecular biology and pharmacology to be part of ambitious cross-functional teams and impact human health.","lastName":"Wang, PhD","objectUrn":"urn:li:member:357783299","geoRegion":"New York City Metropolitan Area","fullName":"Lucia Wang, PhD","firstName":"Lucia","currentPositions":[{"companyName":"Iksuda Therapeutics","description":"Antibody-drug conjugates (ADC) innovation\n\u2022\tFirst chemist hire in the company\u2019s innovation site; managed two preclinical drug development projects in collaboration with external academic and industry research groups. \n\u2022\tDesigned and synthesized linker-payloads with tumor-selective triggers via multi-step organic synthesis (>20 steps), leveraging biocatalysis and asymmetric synthesis for key transformations. \n\u2022\tDemonstrated ability to participate in a fast-paced interdisciplinary team setting, having worked closely with 5+ cross-functional experts in bioconjugation, cell biology and translational sciences. \n\u2022\tReviewed weekly CRO progress reports, proposed solutions to existing synthetic challenges to cut down proposed timelines and pinpointed potential delays. \n\u2022\tContributed to expand company\u2019s IP generation across three different projects by performing extensive prior art searches to assess patentability of potential inventions.","title":"Scientist","companyUrnResolutionResult":{"employeeCountRange":"11-50","headquarters":{"geographicArea":"Tyne and Wear","country":"United Kingdom","city":"Newcastle Upon Tyne","postalCode":"NE4 5BX","line2":"Newcastle Helix","line1":"The Biosphere, Draymans Way"},"website":"http:\/\/www.iksuda.com","flagshipCompanyUrl":"https:\/\/www.linkedin.com\/company\/iksudatherapeutics\/","industry":"Biotechnology Research"},"companyUrn":"urn:li:fs_salesCompany:2541525","tenureAtCompany":{"numYears":2},"startedOn":{"month":6,"year":2022}}],"entityUrn":"urn:li:fs_salesProfile:(ACwAABVTVwMBuMK9NQ2ZsrXN9f5xDLIlCmv6AP0,NAME_SEARCH,Cjza)","profilePictureDisplayImage":{"artifacts":[{"width":100,"fileIdentifyingUrlPathSegment":"100_100\/0\/1656110128608?e=1723075200&v=beta&t=Ca1PeilBz2ybuwqJDN4pylc2wfFmXrZtNUZ-D32oSLI","height":100},{"width":200,"fileIdentifyingUrlPathSegment":"200_200\/0\/1656110128608?e=1723075200&v=beta&t=DtHwkbFvCSeOpLTQMNYFYtqEcTIyOM6IKZe_9sv-9Zc","height":200},{"width":400,"fileIdentifyingUrlPathSegment":"400_400\/0\/1656110128608?e=1723075200&v=beta&t=9p3D7j13c5H3Xo-Q8rtGg5h3hv9hnDSSo_TxB5MF-KA","height":400},{"width":800,"fileIdentifyingUrlPathSegment":"800_800\/0\/1656110128608?e=1723075200&v=beta&t=8ZW7KT5ci4CRaIpieC4jeeP_1FejqmVowqXFHdVXlaE","height":800}],"rootUrl":"https:\/\/media.licdn.com\/dms\/image\/C5603AQGqrYr8nu5UpQ\/profile-displayphoto-shrink_"},"projects":[],"contactInfo":{},"industry":"Biotechnology Research","educations":[{"endedOn":{"year":2022},"degree":"Doctor of Philosophy - PhD","eduId":436404269,"schoolUrn":"urn:li:fs_salesSchool:7832","school":"urn:li:fs_salesSchool:7832","fieldsOfStudy":["Chemical Biology"],"schoolName":"Stevens Institute of Technology","startedOn":{"year":2017}},{"endedOn":{"year":2017},"degree":"Doctor of Pharmacy - PharmD","eduId":294446553,"schoolUrn":"urn:li:fs_salesSchool:15092653","school":"urn:li:fs_salesSchool:15092653","fieldsOfStudy":["Pharmacy"],"schoolName":"Universidad San Pablo-CEU","startedOn":{"year":2012}},{"endedOn":{"year":2016},"degree":"Certificate in Clinical Trials Management","eduId":403554724,"schoolUrn":"urn:li:fs_salesSchool:3881","school":"urn:li:fs_salesSchool:3881","schoolName":"The University of Chicago","startedOn":{"year":2015}}],"skills":[{"numOfEndorsement":0,"name":"Project Management"},{"numOfEndorsement":0,"name":"Collaborative Problem Solving"},{"numOfEndorsement":0,"name":"Patentability"},{"numOfEndorsement":0,"name":"Flow Chemistry"},{"numOfEndorsement":0,"name":"Histochemistry"},{"numOfEndorsement":0,"name":"qRT-PCR"},{"numOfEndorsement":0,"name":"DNA Sequencing"},{"numOfEndorsement":0,"name":"Bioinformatics"},{"numOfEndorsement":0,"name":"Capillary Electrophoresis"},{"numOfEndorsement":0,"name":"DNA Extraction"},{"numOfEndorsement":0,"name":"RNA Isolation"},{"numOfEndorsement":0,"name":"Problem Solving"},{"numOfEndorsement":0,"name":"High-Performance Liquid Chromatography (HPLC)"},{"numOfEndorsement":0,"name":"Computational Chemistry"},{"numOfEndorsement":0,"name":"Biophysical Chemistry"},{"numOfEndorsement":0,"name":"Chemical Biology"},{"numOfEndorsement":0,"name":"Synthetic Organic Chemistry"}],"numOfConnections":191,"patents":[{"inventors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABVTVwMBuMK9NQ2ZsrXN9f5xDLIlCmv6AP0,NAME_SEARCH,Cjza)"}],"description":"A genus of proteolysis-targeting chimeras (PROTACs)-type compounds\/antiestrogens has now been found that act as selective estrogen receptor degraders (SERDs) and estrogen receptor antagonists by degrading and antagonizing ERa in breast cancer cells. The compounds are of the following genus: The compounds described herein exhibit anti-proliferative effects, and are potentially useful, alone or in combination with other therapies, for the treatment of breast cancer. In general, these compounds combine a tight binding ERa targeting ligand tethered to a recognition motif or degron. Once bound, the degron recruits destructive cellular components and the targeted receptor (i.e., ERa) is degraded (i.e., destroyed) or antagonized.","title":"Antiestrogen compounds","url":"https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=WO2019241231&tab=PCTBIBLIO","issuer":"us","issuedOn":{"month":12,"day":19,"year":2019}}],"headline":"Scientist, ADC Innovation at Iksuda Therapeutics","courses":[],"certifications":[],"memberBadges":{"premium":true,"openLink":true,"jobSeeker":false},"flagshipProfileUrl":"https:\/\/www.linkedin.com\/in\/luciawang94","organizations":[],"location":"New York City Metropolitan Area","publications":[{"publishedOn":{"month":7,"day":1,"year":2018},"description":"An effective endocrine therapy for breast cancer is to selectively and effectively degrade the estrogen receptor (ER). Up until now, there have been largely only two molecular scaffolds capable of doing this. In this study, we have developed new classes of scaffolds that possess selective estrogen receptor degrader (SERD) and ER antagonistic properties. These novel SERDs potently inhibit MCF-7 breast cancer cell proliferation and the expression of ER target genes, and their efficacy is comparable to Fulvestrant. Unlike Fulvestrant, the modular protein-targeted chimera (PROTAC)-type design of these novel SERDs should allow easy diversification into a library of analogs to further fine-tune their pharmacokinetic properties including oral availability. This work also expands the pool of currently available PROTAC-type scaffolds that could be beneficial for targeted degradation of various other therapeutically important proteins","url":"https:\/\/pubs.acs.org\/doi\/10.1021\/acsmedchemlett.8b00106","name":"New class of Selective Estrogen Receptor Degraders (SERDs): Expanding the toolbox of PROTAC degrons","publisher":"ACS Medicinal Chemistry Letters","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABVTVwMBuMK9NQ2ZsrXN9f5xDLIlCmv6AP0,NAME_SEARCH,Cjza)"}]},{"publishedOn":{"month":3,"day":1,"year":2019},"description":"Acylboronates represent a very intriguing and rare class of organoboronates. Synthesis of these compounds from readily available substrates under mild conditions and access to novel classes of acylborons has been challenging. We report a novel and concise route to various MIDA acylboronates from terminal alkynes\/alkenes or vinyl boronic esters using unsymmetrical geminal diborylalkanes as key intermediates. The high modularity and mild conditions of this strategy allowed a facile access to acylboronates possessing aliphatic, aromatic as well as the rarer heteroaromatic, alkynyl and \u03b1,\u03b2-unsaturated scaffolds. To the best of our knowledge, this is the first report of chemoselective oxidation of geminal diborons as well as synthesis of an \u03b1,\u03b2-unsaturated acylboronate.","url":"https:\/\/pubs.rsc.org\/en\/content\/articlelanding\/2019\/sc\/c9sc00378a#!divAbstract","name":"A modular and concise approach to MIDA acylboronates\u00a0via\u00a0chemoselective oxidation of unsymmetrical geminal diborylalkanes: unlocking access to a novel class of acylborons\n\n","publisher":"Chemical Science","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABVTVwMBuMK9NQ2ZsrXN9f5xDLIlCmv6AP0,NAME_SEARCH,Cjza)"}]},{"publishedOn":{"month":9,"year":2020},"description":"Selective estrogen receptor degraders (SERDs) represent the last line of treatment for resistant metastatic estrogen receptor-alpha (ER\u03b1)-positive breast cancer. The only clinically approved SERD, Fulvestrant, presents a poor pharmacokinetic profile which limits its overall clinical benefit. This review summarizes recent efforts towards orally available SERDs.","url":"https:\/\/chemistry-europe.onlinelibrary.wiley.com\/doi\/10.1002\/cmdc.202000473","name":"The Quest for Orally Bioavailable Selective Estrogen Receptor Degraders (SERDs)","publisher":"ChemMedChem","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABVTVwMBuMK9NQ2ZsrXN9f5xDLIlCmv6AP0,NAME_SEARCH,Cjza)"}]},{"publishedOn":{"month":3,"day":21,"year":2021},"description":"\u03b1-Hydroxy borons are an underutilized class of compounds and their only previous application involved oxidation into acylborons. Herein, we describe the synthesis of functionalized olefinic \u03b1-hydroxy borons and their utility to enable a novel and regioselective route to hitherto unknown bifunctional halo-boryl tetrahydrofurans\/tetrahydropyrans and \u03b1-halo MIDA boronates. The orthogonally functionalized alicyclic ethers provided a building block-based approach for diversification of the tetrahydrofuran core","url":"https:\/\/doi.org\/10.1039\/D1CC00336D","name":"\u03b1-Hydroxy boron-enabled regioselective access to bifunctional halo-boryl alicyclic ethers and \u03b1-halo borons","publisher":"Chemical Communications","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABVTVwMBuMK9NQ2ZsrXN9f5xDLIlCmv6AP0,NAME_SEARCH,Cjza)"}]},{"publishedOn":{"month":4,"day":26,"year":2021},"description":"A novel C3 acylboron building block; acrylic boronate was successfully prepared and its versatility for catalytic synthesis of several previously inaccessible organoborons is described. Cross-metathesis and Pd-catalyzed coupling of acrylic boronate enabled two complementary routes to highly functionalized \u03b1,\u03b2-unsaturated acylborons and two new types of conjugated borylated products: \u03b1,\u03b2,\u03b3,\u03b4-unsaturated and bis-\u03b1,\u03b2 unsaturated acylborons. The synthetic application of \u03b1,\u03b2-unsaturated acylborons was demonstrated for the first time, thereby providing a general and highly regioselective route to medicinally important 3-boryl pyrazoles. Acrylic boronate also provided a unique bis-electrophilic platform for rapid and chemoselective labeling of cysteines with acylboron tags which are potentially useful for site-selective functionalization and orthogonal ligation of proteins.","url":"https:\/\/doi.org\/10.1039\/D1SC00905B","name":"Acrylic boronate: A multifunctional C3 building block for catalytic synthesis of rare organoborons and chemoselective heterobifunctional ligations","publisher":"Chemical Science","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABVTVwMBuMK9NQ2ZsrXN9f5xDLIlCmv6AP0,NAME_SEARCH,Cjza)"}]},{"publishedOn":{"month":7,"day":22,"year":2022},"description":"Conjugate addition of \u03b1-boron-stabilized carbanions is an underexplored reaction modality. Existing methods require deborylation of geminal di-\/triboryl alkanes and\/or the presence of additional activating groups. We report the 1,4-addition of \u03b1,\u03b1-diboryl carbanions generated via deprotonation of the corresponding geminal diborons. The methodology provided a general route to highly substituted and synthetically useful \u03b3,\u03b3-diboryl ketones. The development of geminal diborons as soft pronucleophiles also enabled their use as acyl anion equivalents via a one-pot tandem conjugate addition\u2013oxidation sequence.","url":"https:\/\/pubs.acs.org\/doi\/full\/10.1021\/acs.joc.2c00914","name":"Boron-Promoted Deprotonative Conjugate Addition: Geminal Diborons as Soft Pronucleophiles and Acyl Anion Equivalents","publisher":"J. Org. Chem","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABVTVwMBuMK9NQ2ZsrXN9f5xDLIlCmv6AP0,NAME_SEARCH,Cjza)"}]},{"publishedOn":{"month":9,"day":8,"year":2022},"description":"Endocrine therapies for breast cancer target ER\u03b1 which is found in more than 70% of breast cancers. Unfortunately, endocrine resistance typically occurs, in which case Selective Estrogen Receptor Degraders (SERDs) represent the last line of treatment for metastatic breast cancer patients. Fulvestrant, the only currently approved SERD and one of the first targeted protein degradation therapies, presents poor drug-like properties which has led to the development of a new generation of oral SERDs. This review summarizes recent progress in the evolution of SERDs, focusing on clinical candidates and their degradation motifs within the broader context of targeted protein degradation therapies","url":"https:\/\/pubs.rsc.org\/en\/content\/articlelanding\/2022\/CS\/D2CS00117A","name":"SERDs: A case study in targeted protein degradation","publisher":"Chem. Soc. Rev.","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABVTVwMBuMK9NQ2ZsrXN9f5xDLIlCmv6AP0,NAME_SEARCH,Cjza)"}]}],"positions":null,"posts":[{"createdAt":1712967000000,"insightId":"acec35be-4069-45b6-9128-b5c67da5ed50","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7184704572379029504","threadUrn":"urn:li:activity:7184704572379029504","reactionsCount":0,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7184704571842203648","message":{"attributes":[],"text":"\ud83d\udc4c"},"rootActivity":{"contentSummaryUnion":{"mediaContentSummary":{"mediaType":"STILLIMAGE","thumnailUrl":"https:\/\/media.licdn.com\/dms\/image\/D5610AQFWLLqejvmTvQ\/image-shrink_1280\/0\/1712243935570?e=1717977600&v=beta&t=guD0my45EFcD4MGsKQu8EuwXVB5LH-nXqh7hifVW20g"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7181671610020474880","message":{"attributes":[{"length":22,"start":36,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:28924"}}},{"length":7,"start":63,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:11110"}}},{"length":14,"start":77,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:bestcompanies"}}},{"length":22,"start":224,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/bit.ly\/3VKCRFa"}}},{"length":15,"start":247,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:bestworkplaces"}}},{"length":14,"start":263,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:gptwcertified"}}},{"length":11,"start":278,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:100bestcos"}}}],"text":"We're No. 53, moving up 26 spots on Great Place To Work US and Fortune's 100 #BestCompanies to Work For list. Thank you to our 50,000+ employees for making us a great place to work seven years in a row. Explore our culture: https:\/\/bit.ly\/3VKCRFa #BestWorkplaces #GPTWCertified #100BestCos"},"entityUrn":"urn:li:share:7181671610020474880"},"entityUrn":"urn:li:share:7184704571842203648"}}},{"createdAt":1712373660000,"insightId":"9dee661b-5cff-4e5c-878c-80c9c38a2b7d","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":4}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7182215917387354113","threadUrn":"urn:li:activity:7182215917387354113","reactionsCount":4,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7182215915739004928","message":{"attributes":[],"text":"How does a cancer vaccine work?\nAfter decades of slow progress, therapeutic vaccines that direct the immune system to attack tumours could soon become a fixture of cancer treatment."},"rootActivity":{"contentSummaryUnion":{"mediaContentSummary":{"mediaType":"STILLIMAGE","thumnailUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E22AQHxK6C91qAaew\/feedshare-shrink_2048_1536\/0\/1711629735260?e=1720051200&v=beta&t=sqW5hRPUP7q6r3yEGZBJpMuovHnJAgxbMeo09IBB2QM"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7179095506017484800","message":{"attributes":[{"start":32,"length":7,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:cancer"}}},{"start":40,"length":9,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:vaccines"}}},{"start":70,"length":14,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:immunotherapy"}}},{"start":110,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/eZABMRtM"}}}],"text":"Crystal clear @Nature primer on #cancer #vaccines the \nquintessential #immunotherapy becoming within reach... https:\/\/lnkd.in\/eZABMRtM "},"entityUrn":"urn:li:share:7179095506017484800"},"entityUrn":"urn:li:share:7182215915739004928"}}},{"createdAt":1716243840000,"insightId":"299296af-c401-4d60-a58a-1c7ea0de5684","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7195992382457192448,7198448616993153024)","threadUrn":"urn:li:ugcPost:7195992382457192448","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Much appreciated Shahram. I will miss you guys as well. Please keep in touch \u2764\ufe0f "},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7195992382457192448"}}},{"createdAt":1716097140000,"insightId":"6ff9e869-4a04-4cd6-aa76-1d35aa4b8b59","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7197671549020033024,7197833226608914434)","threadUrn":"urn:li:ugcPost:7197671549020033024","reactionsCount":0,"commentsCount":1,"canComment":true},"commentary":{"attributes":[],"text":"Kudos to you \ud83d\udc4d"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7197671549020033024"}}},{"createdAt":1715968740000,"insightId":"ba28607e-9a5d-4044-a0a8-f4f70b6590fa","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7195992382457192448,7197294649957339136)","threadUrn":"urn:li:ugcPost:7195992382457192448","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[{"start":0,"length":19,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:168053222"}}}],"text":"Tawaun Lucas, Ph.D. Thanks Tawaun. I wish you the best! \ud83d\ude4c"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7195992382457192448"}}},{"createdAt":1714703340000,"insightId":"2eae21fa-f467-49cf-9ac9-0a5b7ae4dfcc","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7191957301090480128,7191987082204995584)","threadUrn":"urn:li:ugcPost:7191957301090480128","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"So exciting. Good luck in the new role \u270c\ufe0f"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7191957301090480128"}}},{"createdAt":1711320420000,"insightId":"b561aede-a8cf-4bb3-844d-ffefe6d2713c","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7177045116849717248,7177798128912199680)","threadUrn":"urn:li:ugcPost:7177045116849717248","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congrats Yadira"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7177045116849717248"}}},{"createdAt":1711320360000,"insightId":"4c3d742f-b032-48a2-b563-39ba3d280f6b","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":2}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7176259694330601473,7177798059358138368)","threadUrn":"urn:li:ugcPost:7176259694330601473","reactionsCount":2,"commentsCount":1,"canComment":true},"commentary":{"attributes":[],"text":"Congrats Oliver"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7176259694330601473"}}}]}